Trade GeoVax Labs, Inc. - GOVX CFD

Trading Conditions

• Spread: 0.0426
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.001
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 1.4687
• Open: 1.3887
• 1-Year Change: 131.18%
• Day's Range: 1.3887 - 1.4587

GeoVax Labs, Inc. Company profile

About Geovax Labs Inc

GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The Company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Geovax Labs Inc revenues decreased 79% to $386K. Net loss increased from $3M to $18.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $2.4M to $15.6M (expense), General and administrative increase of 63% to $3.6M (expense).

Equity composition

Common Stock $.001 Par, 04/11, 40M auth., 15,699,909 issd. Insiders control approx. 39.31%. IPO: NA. Private Placement: 1997, 4.4M shares @ $1. 9/06, Co. acq. by GeoVax, Inc. & name changed from Dauphin Technology, Inc. 04/10, 1-for-50 reverse split.